Spots Global Cancer Trial Database for operable
Every month we try and update this database with for operable cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| NSABP Biospecimen Discovery Project | NCT01850628 | Breast Cancer | Paclitaxel trastuzumab pertuzumab | 18 Years - | NSABP Foundation Inc | |
| Study of Gemcitabine and Abraxane to Treat Potentially Operable Pancreatic Cancer | NCT01298011 | Resectable Panc... | Gemcitabine and... | 18 Years - | Pancreatic Cancer Research Team | |
| Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy | NCT03387761 | Urothelial Carc... | Ipilimumab Nivolumab | 18 Years - | The Netherlands Cancer Institute | |
| Pharmacodynamic Effects and Predictive Biomarkers With Ruxolitinib in Operable Head and Neck Cancer | NCT02593929 | Head and Neck S... | ruxolitinib | 18 Years - | University of Pittsburgh | |
| Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer. | NCT00721058 | Breast Cancer | CT-scan | 18 Years - | Maastricht Radiation Oncology | |
| Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation | NCT03833154 | Carcinoma, Non-... | Durvalumab Placebo Osimertinib (si... | 18 Years - 130 Years | AstraZeneca | |
| Safety of Toremifene and Tamoxifen Therapy in Premenopausal Patients With Operable Breast Cancer | NCT02344940 | Breast Cancer | Toremifene Tamoxifen | 18 Years - | Shanghai Jiao Tong University School of Medicine | |
| Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation | NCT03833154 | Carcinoma, Non-... | Durvalumab Placebo Osimertinib (si... | 18 Years - 130 Years | AstraZeneca | |
| Preoperative Chemoradiation With Capecitabine and Cetuximab | NCT00297128 | Rectal Cancer | Capecitabine Cetuximab | 18 Years - 80 Years | Austrian Breast & Colorectal Cancer Study Group | |
| CHFR Methylation Status Esophageal Cancer Study | NCT01372202 | Esophageal Canc... | Paclitaxel Cisplatin Oxaliplatin 5-Fluorouracil Radiotherapy Esophagectomy | 18 Years - 75 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| MRD-guided Prognosis Prediction and Adjuvant Treatment Based on CTC and ctDNA in NSCLC | NCT06198868 | Non-small Cell ... | Operable | 18 Years - | Jiangsu Cancer Institute & Hospital | |
| Anti-Proliferative Effects and Genomic Alterations of Abiraterone Acetate Compared to an Aromatase Inhibitor in Post-menopausal HR+ Operable Breast Cancer | NCT01814865 | Post-menopausal... | Abiraterone Ace... Prednisone Aromatase Inhib... | 18 Years - | British Columbia Cancer Agency | |
| Preoperative Chemoradiation With Capecitabine and Cetuximab | NCT00297128 | Rectal Cancer | Capecitabine Cetuximab | 18 Years - 80 Years | Austrian Breast & Colorectal Cancer Study Group | |
| Pharmacodynamic Effects and Predictive Biomarkers With Ruxolitinib in Operable Head and Neck Cancer | NCT02593929 | Head and Neck S... | ruxolitinib | 18 Years - | University of Pittsburgh | |
| MRD-guided Prognosis Prediction and Adjuvant Treatment Based on CTC and ctDNA in NSCLC | NCT06198868 | Non-small Cell ... | Operable | 18 Years - | Jiangsu Cancer Institute & Hospital | |
| Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer. | NCT00721058 | Breast Cancer | CT-scan | 18 Years - | Maastricht Radiation Oncology | |
| Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer | NCT01007890 | Breast Cancer | ChemoFX Assay | 18 Years - | Precision Therapeutics | |
| Safety of Toremifene and Tamoxifen Therapy in Premenopausal Patients With Operable Breast Cancer | NCT02344940 | Breast Cancer | Toremifene Tamoxifen | 18 Years - | Shanghai Jiao Tong University School of Medicine | |
| NSABP Biospecimen Discovery Project | NCT01850628 | Breast Cancer | Paclitaxel trastuzumab pertuzumab | 18 Years - | NSABP Foundation Inc | |
| Pharmacodynamic Effects and Predictive Biomarkers With Ruxolitinib in Operable Head and Neck Cancer | NCT02593929 | Head and Neck S... | ruxolitinib | 18 Years - | University of Pittsburgh | |
| Safety of Toremifene and Tamoxifen Therapy in Premenopausal Patients With Operable Breast Cancer | NCT02344940 | Breast Cancer | Toremifene Tamoxifen | 18 Years - | Shanghai Jiao Tong University School of Medicine | |
| Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy | NCT03387761 | Urothelial Carc... | Ipilimumab Nivolumab | 18 Years - | The Netherlands Cancer Institute | |
| MRD-guided Prognosis Prediction and Adjuvant Treatment Based on CTC and ctDNA in NSCLC | NCT06198868 | Non-small Cell ... | Operable | 18 Years - | Jiangsu Cancer Institute & Hospital | |
| Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer | NCT01007890 | Breast Cancer | ChemoFX Assay | 18 Years - | Precision Therapeutics |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
